Eczematous Dermatosis and Thrombocytosis Induced by Efalizumab: Two New Side Effects
| Autor: | G. Lemasson, Laurent Misery, J.F. Abgrall, D. Firmin, A.M. Roguedas |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Thrombocytosis Plaque psoriasis medicine.medical_specialty business.industry Injections Subcutaneous Efalizumab Eczema Antibodies Monoclonal Dermatology Antibodies Monoclonal Humanized medicine.disease Psoriasis medicine Humans Female business health care economics and organizations Aged medicine.drug |
| Zdroj: | Dermatology. 217:203-206 |
| ISSN: | 1421-9832 1018-8665 |
| Popis: | Efalizumab was authorized to be put on the market in France starting July 21, 2005. Its efficacy and tolerance profile in plaque psoriasis at a dose of 1 mg·kg–1 weekly in a subcutaneous injection have been studied in phase III trials. At the current moment, more than 3,500 patients have been included in clinical trials. Flu-like symptoms (fever, chills, headaches, nausea, vomiting, myalgia) are the most frequent adverse events. On the skin, a localized papular rash or the aggravation of the psoriasis in an edematous or even pustular form are the two most regularly observed complications. At the biological level, hyperlymphocytosis and a temporary increase in alkaline phosphatases without clinical consequences are the most frequent anomalies. We report 2 adverse events under efalizumab that to our knowledge have never been described: a case of an eczematous rash and a case of thrombocytosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|